Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Patients With Refractory Cytomegalovirus Infection Following Allo-HSCT: a Prospective, Multicenter, Randomized, Controlled Clinical Trial

NCT07511127 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07511127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07511127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Patients With Refractory Cytomegalovirus Infection Following Allo-HSCT: a Prospective, Multicenter, Randomized, Controlled Clinical Trial
Lead sponsor
Ruijin Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
February 28, 2026
Completion date
December 31, 2028
Enrollment
218 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy